Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gevokizumab in active inflammatory, erosive osteoarthritis of the hand
NCT01683396Phase 2Completed
- Sponsor
- XOMA
- Start
- Jul 2012
- Primary completion
- Feb 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in erosive osteoarthritis of the hand (EOA) comparing Gevokizumab with Placebo (2 arms). Primary endpoint: Percent change from baseline in AUSCAN pain score at Day 84. Started Jul 2012; status: completed.
02
Drugs
gevokizumab
03
Conditions
erosive osteoarthritis of the hand (EOA)
Beyond the preview
Go deeper on NCT01683396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01683396.